PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Bill & Melinda Gates Foundation funding for MIP Discovery

MIP Discovery – a company focused on detection reagents – has received a significant grant of funds from the Bill & Melinda Gates Foundation.

Incorporating the company’s proprietary nanoMIP technology, the project will use MIP Discovery’s animal/cell-free detection reagents as an alternative, and possible improvement over antibodies. This will subsequently quickly enable high-volume, low-cost diagnostic tests throughout low and middle-income countries.

This process will be especially useful during the kind of endemic or pandemic outbreaks witnessed in recent times. Indeed, dispersing of effective diagnostic testing is essential to managing disease outbreaks at regional or global levels. The challenge is being able to develop diagnostics rapidly – ones that can also be upscaled in a brief period of time for widespread use.

With this in mind, MIP Discovery’s imprinted polymer technology is able to meet this requirement for speed and scale, and the company is currently optimising processes that will be significantly faster than novel antibody production.

Meanwhile, MIP Discovery is keen to reduce current timelines to allow the design and scale-up of novel detection reagents in under four weeks. If this milestone is achieved, nanoMIP detection reagents can then be deployed using high-throughput diagnostic platforms or lateral flow devices.

Stephane Argivier, chief executive officer, of MIP Discovery, believes the project can be successful: “COVID-19 taught the world the importance of pandemic preparedness, particularly the importance of the effective deployment of diagnostic testing.

“We are proud to be aligned with the foundation and other partners such as Flexotronix, a Sapphiros company, in developing new approaches to delivering diagnostic disease testing on a global basis. Our proprietary nanoMIP technology will redefine how the world will respond to endemic and pandemic crises, whether natural or otherwise.”

Mike Evans, chairman, MIP Discovery. “Pandemics are very much global events that require rapid global responses. This program, driven by the foundation funding is a key step in the development of high-volume, cost-effective IVD tools that provide a rapidly scalable solution to a sudden demand for any infectious disease crisis, whether these are known conditions such as Ebola or emerging viruses similar to recent strains of COVID-19.”

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026